GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Awakn Life Sciences Corp (XCNQ:AWKN) » Definitions » Debt-to-EBITDA

Awakn Life Sciences (XCNQ:AWKN) Debt-to-EBITDA : 0.00 (As of Apr. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Awakn Life Sciences Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Awakn Life Sciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Apr. 2024 was C$0.00 Mil. Awakn Life Sciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Apr. 2024 was C$0.00 Mil. Awakn Life Sciences's annualized EBITDA for the quarter that ended in Apr. 2024 was C$-2.08 Mil. Awakn Life Sciences's annualized Debt-to-EBITDA for the quarter that ended in Apr. 2024 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Awakn Life Sciences's Debt-to-EBITDA or its related term are showing as below:

XCNQ:AWKN's Debt-to-EBITDA is not ranked *
in the Biotechnology industry.
Industry Median: 1.375
* Ranked among companies with meaningful Debt-to-EBITDA only.

Awakn Life Sciences Debt-to-EBITDA Historical Data

The historical data trend for Awakn Life Sciences's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Awakn Life Sciences Debt-to-EBITDA Chart

Awakn Life Sciences Annual Data
Trend Jan21 Jan22 Jan23 Jan24
Debt-to-EBITDA
-0.12 -0.11 -0.44 -

Awakn Life Sciences Quarterly Data
Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.66 - - - -

Competitive Comparison of Awakn Life Sciences's Debt-to-EBITDA

For the Biotechnology subindustry, Awakn Life Sciences's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Awakn Life Sciences's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Awakn Life Sciences's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Awakn Life Sciences's Debt-to-EBITDA falls into.



Awakn Life Sciences Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Awakn Life Sciences's Debt-to-EBITDA for the fiscal year that ended in Jan. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -3.908
=0.00

Awakn Life Sciences's annualized Debt-to-EBITDA for the quarter that ended in Apr. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -2.076
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Apr. 2024) EBITDA data.


Awakn Life Sciences  (XCNQ:AWKN) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Awakn Life Sciences Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Awakn Life Sciences's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Awakn Life Sciences Business Description

Traded in Other Exchanges
Address
301?217 Queen Street West, Toronto, ON, CAN, M5V 0R2
Awakn Life Sciences Corp is a clinical-stage biotechnology company intended to develop therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder. The Company focuses on Alcohol Use Disorder (AUD), a condition affecting the people in the US and key international markets and many people globally for which the current standard of care is inadequate, enabling to provide breakthrough therapeutics to addiction sufferers in desperate need.

Awakn Life Sciences Headlines

No Headlines